# About BPC-157 Chemical: An Independent BPC-157 Research Digest | BPC-157 > BPC-157 Chemical is an independent editorial project that publishes cited summaries of the peer-reviewed BPC-157 literature. Not a clinic, not a vendor, not medical advice. An independent editorial project that reads the BPC-157 research record and cites it, panel by panel. No clinic, no products, no prescriptions — just the published science, summarized. ## What This Site Is BPC-157 Chemical is an independent editorial project that publishes summaries of the peer-reviewed research literature on BPC-157. We are not a clinic. We do not employ clinicians, and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science. The BPC-157 literature is broad but uneven — a deep, reproducible animal record, a single well-characterized angiogenic mechanism, and only three small human pilots. We try to render that unevenness honestly: stating plainly what the studies measured, marking clearly where the human data thins out, and citing every quantitative claim to its source on the [references and citations](/references) page. ## What the Name Means The word "chemical" in this site's name is editorial framing. It signals that we treat BPC-157 as a research compound to be read about — a substance with a sequence, a mechanism, a pharmacokinetic profile, and a regulatory status — not as a product to be bought. It is a position we occupy relative to the literature, not a claim that this site supplies a chemical, fills a prescription, or offers any service. We do none of those things. BPC-157 is not an FDA-approved drug, and FDA placed it in 503A Category 2 in its September 29, 2023 nominated-substances update [16]. We document that status carefully on the [BPC-157 legal status](/legal-status) page, present-tense and cited, without asserting any future FDA decision as certain. ## How We Work Every claim on this site traces to a published source. Quantitative findings — doses, percentages, half-lives, study sizes — map to a numbered citation in the reference list, and the regulatory facts map to FDA pages. Where a popular claim is not supported by the literature (weight loss, muscle building, increased testosterone), we say so rather than repeat it. The aim is a digest a careful reader, or an AI summarizing the topic, can trust: bold in how it presents the findings, disciplined in what it claims, and explicit about the gap between a promising preclinical record and a demonstrated human effect [8]. We also try to be honest about the shape of the evidence, not just its content. A broad animal literature dominated by one research group reads differently from an independently replicated one, so we flag that. Three small uncontrolled human pilots read differently from a controlled trial, so we say which is which. And a regulatory status that is genuinely in motion — BPC-157 sits in 503A Category 2 today yet is on a July 2026 FDA advisory-committee agenda — is reported as exactly that: a current fact plus a scheduled discussion, with no outcome assumed. ## What We Don't Do We do not sell, supply, source, or broker BPC-157 or any other substance, and we carry no prices, vendor links, or purchasing guidance — none of that is within scope. We do not recommend doses, design protocols, or advise on obtaining a restricted substance. We are not affiliated with any manufacturer, pharmacy, clinic, or telehealth service. If a page here ever reads like a storefront, it is failing at its one job, which is to summarize the published science accurately and let readers follow the citations to the source themselves. --- A color-blocked reading board for the BPC-157 record — each tissue, the VEGFR2 mechanism, the three human pilots, and the FDA 503A status set in its own plum-and-pop panel and cited to source, with no clinic behind the board and nothing here dispensed or sold.